In the past week, OCGN stock has gone down by -3.03%, with a monthly decline of -28.09% and a quarterly surge of 136.56%. The volatility ratio for the week is 11.65%, and the volatility levels for the last 30 days are 12.33% for Ocugen Inc The simple moving average for the last 20 days is -15.53% for OCGN stock, with a simple moving average of 92.81% for the last 200 days.
Is It Worth Investing in Ocugen Inc (NASDAQ: OCGN) Right Now?
The 36-month beta value for OCGN is at 3.53. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for OCGN is 251.67M, and currently, shorts hold a 17.97% of that float. The average trading volume for OCGN on April 29, 2024 was 9.28M shares.
OCGN) stock’s latest price update
Ocugen Inc (NASDAQ: OCGN)’s stock price has increased by 8.47 compared to its previous closing price of 1.18. However, the company has seen a -3.03% decrease in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-04-26 that MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410 for the treatment of geographic atrophy (Phase 1/2 ArMaDa clinical trial), and OCU410ST for the treatment of Stargardt disease (Phase 1/2 GARDian clinical trial) at The Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle, WA from May 5-9, 2024.
Analysts’ Opinion of OCGN
Many brokerage firms have already submitted their reports for OCGN stocks, with Chardan Capital Markets repeating the rating for OCGN by listing it as a “Buy.” The predicted price for OCGN in the upcoming period, according to Chardan Capital Markets is $3.50 based on the research report published on March 01, 2023 of the previous year 2023.
Mizuho, on the other hand, stated in their research note that they expect to see OCGN reach a price target of $5. The rating they have provided for OCGN stocks is “Buy” according to the report published on August 23rd, 2022.
ROTH Capital gave a rating of “Buy” to OCGN, setting the target price at $8 in the report published on June 15th of the previous year.
OCGN Trading at 2.15% from the 50-Day Moving Average
After a stumble in the market that brought OCGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.19% of loss for the given period.
Volatility was left at 12.33%, however, over the last 30 days, the volatility rate increased by 11.65%, as shares sank -21.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +91.90% upper at present.
During the last 5 trading sessions, OCGN fell by -3.03%, which changed the moving average for the period of 200-days by +113.73% in comparison to the 20-day moving average, which settled at $1.4972. In addition, Ocugen Inc saw 122.61% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OCGN starting from Zhang Junge, who purchase 200,278 shares at the price of $0.50 back on Jun 14 ’23. After this action, Zhang Junge now owns 1,077,182 shares of Ocugen Inc, valued at $99,999 using the latest closing price.
Stock Fundamentals for OCGN
Current profitability levels for the company are sitting at:
- -10.86 for the present operating margin
- 0.84 for the gross margin
The net margin for Ocugen Inc stands at -10.24. The total capital return value is set at -1.38. Equity return is now at value -103.61, with -74.16 for asset returns.
Based on Ocugen Inc (OCGN), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -8.94. The debt to equity ratio resting at 0.17. The interest coverage ratio of the stock is 52.3.
Currently, EBITDA for the company is -64.83 million with net debt to EBITDA at 0.5. When we switch over and look at the enterprise to sales, we see a ratio of 49.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.51.
Conclusion
In conclusion, Ocugen Inc (OCGN) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
